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REVIEW
Advances in Gene Therapy for Diseases of the Eye
Lolita Petit,1 Hemant Khanna,1,2 and Claudio Punzo1,2,*
1Department of Ophthalmology and Gene Therapy Center, and 2Department of Neurobiology,
University of Massachusetts Medical School, Worcester, Massachusetts.
Over the last few years, huge progress has been made with regard to the understanding of molecular
mechanisms underlying the pathogenesis of neurodegenerative diseases of the eye. Such knowledge has
led to the development of gene therapy approaches to treat these devastating disorders. Challenges
regarding the efficacy and efficiency of therapeutic gene delivery have driven the development of novel
therapeutic approaches, which continue to evolve the field of ocular gene therapy. In this review article,
we will discuss the evolution of preclinical and clinical strategies that have improved gene therapy in the
eye, showing that treatment of vision loss has a bright future.
INTRODUCTION
VISION IS CONSIDERED by many to be the most im-
portant of our five senses. It is a highly complex
process that requires the coordinated activity of
numerous components in the eye and the brain.
The initial steps are performed by the retina, which
is the light-sensitive neuronal tissue situated at
the back of the eye. When light reaches the retinal
rod and cone photoreceptors, photons are absorbed
by a photopigment, which activates a cascade that
converts the light signal into an electrochemical
signal. This is done in collaboration with the reti-
nal pigment epithelium (RPE), which regenerates
the visual chromophore. Electrochemical signals
are then transferred through bipolar cells to gan-
glion cells, where they are converted into action
potentials that are sent to the brain.1 Consistent
with the crucial role of the retina in vision, the
majority of diseases that lead to blindness are
caused by an acquired or inherited degeneration of
the retina.
As a gene therapy target, the retina is a particu-
larlywell-suited organ for therapeutic interventions.
The retina is a small tissue, highly compartmenta-
lized, immune-privileged, and easily accessible. Op-
tical transparency of the eye enables safe evaluation
of reporter gene expression and therapeutic effects
by noninvasive methods,2 such as electroretinog-
raphy (ERG), funduscopy, and optical coherence
tomography (OCT). These favorable factors, along
with a thorough knowledge of the molecular path-
ogenesis of many retinal diseases, the development
and characterization of animal models that mimic
human diseases, and the advances in gene delivery
tools, have fueled a rapid development of multiple
gene therapy strategies for several forms of re-
tinopathies. This review is focused on emerging
strategies that use gene therapy to combat vision
loss, particularly for the treatment of retinal dis-
eases caused by mutations that directly affect the
photoreceptors.
GENE REPLACEMENT THERAPY
FOR LCA2: THE FIRST SUCCESS
OF OCULAR GENE THERAPY
The most successful example of ocular gene ther-
apy was the gene replacement therapy for RPE65,
Leber’s congenital amaurosis 2 (LCA2), an early
onset form of autosomal recessive retinal degenera-
tion caused bymutations in theRPE65 (RPE-specific
65kDa protein) gene. RPE65 encodes an isomerase
expressed mainly in the RPE that is critical for
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recycling the visual chromophore involved in the
visual cycle.3Mutations inRPE65 result in defective
visual pigment formation (both rhodopsin and cone
opsin),4 hence severely affecting photoreceptor
function and vision.5 Large amounts of opsin apo-
protein in photoreceptors, as well as accumulation
of toxic retinyl esters in the RPE, are thought to
promote the progressive death of photoreceptors.
Clinical phenotype analyses revealed that the de-
generative component of RPE65-LCA2 starts at an
early age in patients with a functional loss that is
much larger than expected for the amount of cells
retained.6 It is this phenotype that provided a very
good starting point for a gene-based intervention for
this disorder.
Several murine and canine models of LCA2
have shown marked functional benefits with gene
therapy.6 In particular, results obtained in the
Rpe65-/- Briard dog yielded deep excitement in
the field because of its more human-like eye anat-
omy and immune system. The first study was
carried out by subretinal delivery of recombinant
adeno-associated virus (AAV) 2 vectors express-
ing the wild-type canine Rpe65 cDNA under the
control of the ubiquitous chicken b-actin (CBA)
promoter.7 This study revealed a dramatic im-
provement in photoreceptor function and vision in
treated dogs. Subsequent dog studies extended
the use of other AAV serotypes, including AAV1,
AAV4, and AAV5, and different promoters.8–18 Im-
provement of vision persisted for over 11 years after
a single injection of the vector.16 In addition, suc-
cessful restoration of both cone and rod functionwas
achieved in 20 out of 22 treated eyes at more
advance stages of the disease (dogs over 2 years
of age).12,14,16,18
Based on these preclinical studies, four separate
phase I–II clinical trials were initiated, which yiel-
ded promising results after subretinal adminis-
tration of AAV2-hRPE65 vectors (NCT00481546,
NCT00516377, NCT00643747, NCT00749957;
Supplementary Table S1; Supplementary Data
are available online at www.liebertpub.com/hum).
Although the designs of these studies varied with
respect to the use of the promoter driving the
expression of RPE65, the volume of vector in-
jected, and the surgical protocol, the data collec-
tively demonstrated safety of AAV2 delivery to the
retina.16,17,19–24 Remarkably, patients in all trials
exhibited several aspects of visual improvements
within a few months after treatment, though with
varying degrees. These results generated excite-
ment in the field. Subsequent treatment of the
second eye of LCA2 patients previously treated
with the same vector demonstrated both safety
and efficacy, indicating that subretinal adminis-
tration of AAV2 is feasible even in the case of pre-
existing immunity against the vector capsid.25
These promising results justified the initiation of a
phase III clinical trial (NCT00999609) evaluating
the treatment of both eyes in patients over 8 years of
age. Thus far the trial is confirming the previ-
ous visual improvements (SparkTherapeutics Press
Release 10/05/2015). AAV2-hRPE65 is expected to
become the first approved gene therapy product in
the United States, marking a pivotal step for the
entire gene therapy field.26 In addition, a phase I/II
clinical trial (NCT01496040) evaluating the effects
of an alternative vector with increased specificity
for the RPE (AAV4-RPE65-hRPE65) was recently
completed.
Although the pioneering RPE65 trials went far
beyond the primary expectations, they uncov-
ered a number of unforeseen challenges, mainly
in the magnitude and the longevity of the thera-
peutic benefits. Contrary to the remarkable dis-
ease rescue obtained in the Rpe65-/- dog, none of
the treated RPE65-LCA eyes in any clinical trials
have shown improvements in retinal function
measurable by full-field ERG.6 The reason for this
species-specific difference remains unknown, but
is likely related to the extent of disease progres-
sion in patients at the time of treatment. Unlike
early-onset degeneration in patients with LCA2,
the RPE65-mutant dogs exhibit no evidence of
photoreceptor degeneration for up to 1.5 years of
age and show good preservation of photoreceptors
in the peripheral retina at 5–7 years of age (57%
of rods and 85% of total cones).6,14,15 Severe pho-
toreceptor degeneration in patient retinas at the
time of treatment may have limited the success of
the gene therapy strategies. Nonetheless, a recent
study investigating efficiency of AAV2-hRPE65 de-
livery in older Rpe65-mutant dogs showed no cor-
relation between improvement in ERG, the age of
the dogs at the time of treatment, and the number
of surviving photoreceptors. These results suggest
that additional factors could influence the degree of
rescue associated with RPE65 treatment.14 Health
of the remaining RPE and photoreceptor cells may
be a factor to consider. One might also predict that
disease progression negatively impacts the mean
transduction efficiency (i.e., the percentage/density
of total RPE cells transduced and the level of
RPE65 expression in transduced cells), thereby
reducing the magnitude of rescue. In the animal
studies, the effect of RPE65 replacement is highly
dose dependent,17 with lower doses associated with
improvement in visual-guided behavior without de-
tectable rescue by ERG recordings.14,17 Inefficient
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transduction is in agreement with reports of in-
complete restoration of dark adaptation in pa-
tients after gene therapy,17,22,27 indicating that
partial restoration of the visual cycle may be in-
sufficient to meet the demand of the surviving
photoreceptors. Consistent with that, Bainbridge
et al. found that RPE65 RNA level in the human
eye is 2.5 times greater than that in the dog eye,
which suggests that the demand for RPE65 by the
human retina is higher.17
A recent long-term assessment of photoreceptor
preservation in treated RPE65-LCA2 patients also
questioned the longevity of the therapeutic effects.
Two studies (NCT00481546 and NCT00643747)
demonstrated that, despite visual improvement,
photoreceptor death remained unchanged and fol-
lowed the expected natural history of the dis-
ease.16,17,22 Disappointingly, retinal degeneration
was associated with a progressive contraction of
the areas of improved vision over a period of 5–6
years after intervention22 and with a sharp decline
of retinal sensitivity by 3 years postinjection in a
subset of treated patients,17 indicating a possible
loss of the functionally rescued cells. However, loss
of a therapeutic effect at 2–4 years posttreatment
has not yet been reported by Spark Therapeutics,
potentially reflecting differences in vector design
or manufacturing. Nonetheless, the loss of the
therapeutic effect observed by Jacobson et al.22 and
Bainbridge et al.17 has important implications for
the evaluation of any retinal gene therapy, and
several hypotheses have been formulated to ex-
plain it. Cideciyan et al. proposed that gene re-
placement therapy does not slow the degenerative
component of the disease if the intervention is
initiated after a threshold of accumulative molec-
ular changes has been reached in RPE and/or pho-
toreceptors.16 Alternatively, the continuous changes
that occur in the tissue not exposed to the vector
could have overcome the small number of stably
rescued RPE/photoreceptors in these patients.28
Should results of the phase III clinical trial confirm
the lack of long-term efficacy, appreciating the
mechanism will be important for managing expec-
tations about the benefits of gene therapy for each
patient, as well as for designing strategies to im-
prove the durability of the treatment. If a ‘‘point of
no return’’ exists, alleviating stress in cells before
treatmentmay be a solution to extend the efficacy of
the gene therapy. Otherwise, it may be necessary to
increase the number of transduced cells and also
protect rescued photoreceptors against secondary
degeneration. Such strategies are being devel-
oped for use in other retinal diseases28,29 and
could be adapted to the RPE65 deficiency.
RECENT PROGRESS IN CLINICAL
APPLICATIONS OF RETINAL GENE
REPLACEMENT THERAPY
Gene replacement therapy for Mer
proto-oncogene tyrosine kinase (MERTK)-
and Rab-escort protein 1 (REP1)-associated
inherited retinal diseases
Pioneering results of RPE65-LCA2 trials laid
the groundwork for the initiation of trials for dif-
ferent forms of inherited retinopathies caused by
mutations in another RPE-specific gene (MERTK
retinitis pigmentosa) and in a gene required for
both RPE and photoreceptor survival (REP1
choroideremia).
MERTK is involved in the engulfment of outer
segment debris by the RPE. Patients with MERTK
deficiency exhibit severe dysfunction of both rods
and cones, associated with an early-onset and pro-
gressive degeneration of photoreceptors. In the first
clinical safety study for MERTK retinitis pig-
mentosa (NCT01482195),30 six patients received a
submacular injection of AAV2-VMD2-hMERTK, in
which theMERTK cDNA was expressed under the
control of the RPE-specific VMD2 (vitelliform mac-
ular dystrophy) promoter. No complications attrib-
uted to the vector were observed, and three patients
displayed improved visual acuity in the treated
eye within the first week/month postintervention.
However, the improvement declined to baseline 2
years posttreatment in two of the patients. Contrary
to the LCA2 gene therapy studies, this functional
decline was not associated with major changes in
retinal thickness, as assessed by OCT. However,
variability in OCT measurements in these patients
with nystagmus was very large. It is possible that
the quality of treatment, including the number of
cells treated and expression levels of MERTK, may
have been too low to promote long-term benefits.
Recently, promising results from a multicen-
ter phase I/II study of AAV2-mediated gene re-
placement therapy for choroideremia (CHM) were
reported (NCT01461213),31,32 strengthening the
use of gene therapy for retinal diseases. CMH is
a severe X-linked recessive disorder leading to
blindness through progressive degeneration of
the choroid, RPE, and photoreceptors caused by
the loss of function of the Rab escort protein 1
(REP1). CHM can be identified in childhood;
however, it differs fromRPE65-LCA2 in thatmost
patients retain 20/20 vision because of fairly well-
preserved central retinal cones until the fifth de-
cade of life. The main objective is to preserve this
area from further degeneration, which will require
long-term follow-up to detect the outcome of the
gene therapy. Importantly, no retinal thinning or
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loss of visual acuity was observed despite the sur-
gically induced retinal detachment, establishing a
favorable safety profile for this gene transfer pro-
tocol targeting the fovea. In addition, at 6 months
posttreatment, significant improvement in retinal
sensitivity was noted in the five patients who re-
ceived the highest vector dose, as well as large
gains in visual acuity in the two patients in whom
visual acuity was already reduced at baseline.
Preservation or gains in visual acuity were sus-
tained until at least 3.5 years after treatment,
while, over the same period, visual acuity in the
control noninjected eyes decreased progressively.32
It will be interesting to see if photoreceptor de-
generation is prevented in these patients in a long-
term follow-up examination. A 30-patient phase II
study (NCT02341807) has started to further as-
sess the functional and anatomical outcomes. Ad-
ditionally, a phase I/II clinical trial using AAV5, a
serotype with increased tropism for photorecep-
tors as compared with AAV2, is planned (Horama/
Nantes Hospital, France). This approach may max-
imize the efficacy of the therapy as it was demon-
strated that rod photoreceptors could degenerate
independently from the RPE.33,34
Additional clinical trials of retinal
gene replacement therapy
To date, eight clinical trials testing gene re-
placement for four other retinal diseases are in
progress (Supplementary Table S1). All of them
build on the existing AAV2 platform, with the ex-
ception of two trials using the equine infectious
anemia virus (EIAV)-based lentiviral vectors for
the treatment of Stargardt disease (NCT01367444)
andUsher type 1B syndrome (NCT01505062). These
diseases are caused by mutations in the ABCA4 and
MYO7A genes respectively, which are too large to be
packaged in an AAV.35 Lentivirus, which has a
higher cargo capacity than AAV, has therefore been
chosen as an alternative to AAV.
ABCA4 is localized in the outer segments of
photoreceptors and acts as an important mem-
brane transporter for the recycling of the visual
chromophore. ABCA4 loss of function is associated
with accumulation of toxic products in RPE cells,
followed by severe RPE andmacular photoreceptor
death. A proof-of-concept study in the Abca4-/-
mice demonstrated beneficial effects after sub-
retinal injection of EIAV-Abca4 at postnatal day
(PN)4–PN5.36 MYO7A is expressed in cochlear
hair cells of the inner ear as well as in retinal
photoreceptors and the RPE,37 where it plays a role
in multiple cellular processes, including endocyto-
sis and cellular transport. Although the amount of
MYO7A in photoreceptors is lower than that in the
RPE, photoreceptors are affected before RPE cells
in patients with Usher1B, indicating that photo-
receptors are important cells to target in this dis-
ease as well. The ability of LV-MYO7A to restore
RPE abnormalities has been shown in theMyo7a-/-
mouse after subretinal injection of the vector at
birth.38,39 However, a major concern of lentiviral
vectors for clinical use is its relative inability to
transduce postmitotic photoreceptors. Physical bar-
riers, which are not present in the newborn rodent
retina, have been hypothesized to dramatically
limit access of the large lentivirus particles to adult
photoreceptors.40 At this point the results of these
two clinical trials remain unknown. Nonetheless,
these results will provide valuable information not
only regarding the efficacy of lentivirus in the ret-
ina, but also to determine whether lentivirus may
serve as a safe alternative vector for RPE diseases
in which high level of transgene expression is
required.
PRECLINICAL ADVANCES IN GENE-SPECIFIC
THERAPY FOR PHOTORECEPTOR DISEASES
One of the major challenges over the next 20
years will be to initiate treatment of many retinal
disorders in which the disease-causingmutation is
primarily expressed in photoreceptors. Compared
with RPE-associated diseases, primary photore-
ceptor dystrophies have been considered as more
difficult to treat. This is because photoreceptors
are directly impaired by the genetic mutation and,
second, because the efficiency of photoreceptor
transduction is relatively lower compared with that
of RPE cells.41 AAV2 and lentiviral vectors, though
excellent vectors for transducing the RPE, were
found to be inefficient in transducing photorecep-
tor cells.42,43 However, several novel AAV serotypes
have been identified and characterized. Among
these, AAV5, 7, 8, 9, and rh10, as well as vectors
with modified capsid proteins, show remarkable
improvement in terms of photoreceptor trans-
duction efficiency when compared with AAV2 (for
review, see refs.41,44). The main question that re-
mains to be answered now is whether the use of
these serotypes can offer clinical benefits. To illus-
trate advances in gene-specific therapies for reces-
sive photoreceptor diseases, we will describe two
approaches in more detail: (1) the promising appli-
cation of gene therapy for the treatment of station-
ary disorders, in particular cone disorders, and (2)
the novel approaches for the treatment of progres-
sive retinal dystrophies initiated by defects that are
either in rods or in both rods and cones.
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Gene replacement therapy in animal models
of stationary photoreceptor disorders
Despite the fact that stationary photoreceptor
diseases are relatively rare, they are ideal trans-
lational models for the development of gene re-
placement therapies targeting photoreceptors.
Stationary disorders are associated with congeni-
tal retinal dysfunction and can thus be diagnosed
early. Their slowly progressive degenerative na-
ture presents therefore a wide window of opportu-
nity for intervention and effects of the therapy can
be rapidly assessed through the restoration of ret-
inal function.
Achromatopsia (ACHM) is an autosomal reces-
sivedisease associatedwith severe cone dysfunction,
caused by a loss of function of some cone-specific
proteins. To date, four small45–48 and three large
animal models29,49,50 of ACHM have been suc-
cessfully treated using AAV-mediated gene re-
placement therapy (Supplementary Table S2).
The first report of efficient gene therapy for
ACHM was obtained in the cpfl3 (cone photore-
ceptor functional loss 3) mouse model of GNAT2
(guanine nucleotide binding G-protein) deficien-
cy.45 This mouse model retains *25% of the nor-
mal cone-mediated ERG response up to 4 weeks
of age with no detectable responses by 9 months
of age. In contrast, cone structural integrity is
maintained for at least 14 weeks. Subretinal in-
jection of AAV5 encoding the mouse Gnat2 under
the control of the human red green cone opsin
promoter (AAV5-PR2.1-mGnat2) at PN23-PN29
in cpfl3 mice restored cone ERG responses and
visual-guided behavior to levels indistinguishable
from age-matched controls in 80% of treated eyes,
for at least 7months. Interestingly, when the cpfl3
mice were treated at later stages of the disease (>9
months of age), the degree of rescue was variable,
with only one eye showing cone ERG responses
within the normal range.45
Consistent with this, Carvalho et al. demon-
strated that an optimal therapeutic window is
present in the Cngb3-/- (cone-specific cyclic nucle-
otide gated channel subunit b3) mouse model of
ACHM,48 in which cone degeneration is comparable
to that of the cpfl3 mice. While subretinal injection
of AAV8-mCAR-hCNGB3, expressing CNGB3 un-
der the control of the mouse cone arrestin promoter
at PN15, resulted in long-term restoration of cone-
mediated ERG responses up to 90% of wild-type
levels, treatment at PN90 and PN180 resulted in
functional rescue at 70–80% and 60–70% of wild-
type levels, respectively. Restoration of visual acu-
ity was not possible after PN90. Komaromy et al.
also showed restoration of vision in two canine
models of CNGB3-ACHM using AAV5, marking an
important milestone in the photoreceptor gene
therapy field.49 However, the magnitude and lon-
gevity of the therapy in dogs was also age depen-
dent.29,49 Younger dogs (<6 months) treated with
AAV5-PR2.1-cCngb3 displayed the most sustained
therapeutic effects, with a restoration of cone
function up to 5–10% of wild-type levels, and a
restoration of visual-guided behavior in bright
light. Therapeutic effects were maintained for at
least 33 months postinjection in two dogs. In con-
trast, only two out of seven dogs treated with less
efficient vectors showed any sustained response,
whereas the others had either a transient or no
functional cone response. At older ages, only 1 dog
out of 11 showed any sustained response. The au-
thors hypothesized that the failure might result
from the improper reassembly of the components of
the phototransduction cascade when retinas were
treated at more advanced stages of the disease.
Combination of gene therapywith administration of
the ciliary neurotrophic factor (CNTF), which pro-
motes outer segment deconstruction and recon-
struction, increased the efficacy and durability of
gene therapy in older dogs.29 CNTF alone also
transiently restored cone function,29,51 an effect not
reproduced in five patients with CNGB3-ACHM.52
Taken together these results indicate that the
health of photoreceptor cells at the time of inter-
vention and the associated efficacy in transgene
expression could be limiting factors for a functional
rescue after gene therapy in ACHM. Nonetheless,
accurate selection of patients, choice of area for
treatment, and selection of an optimal vector system
may realistically allow for a favorable outcome in
humans. Based on the encouraging results using
animal models, Applied Genetic Technologies Cor-
poration is conducting a phase I–II clinical trial to
evaluate the potential of an optimized vector sys-
tem53 (AAV2tYF-PR1.7-codon-optimized hCNGB3
[Supplementary Table S1] for the treatment of
CNGB3-ACHM).
X-linked retinoschisis (XLRS) is characterized
by compromised retinal integrity and a subsequent
slow loss of central photoreceptors. Juvenile XLRS
is caused by loss-of-function mutations in the RS1
gene (retinoschisin), which encodes for a protein
primarily expressed and secreted from photore-
ceptors and bipolar cells. The function of RS1 is
unknown, but the protein is thought to play a role
in cell adhesion and in the organization of the
photoreceptor-bipolar cell synapse.54 Numerous
studies have shown that delivery of theRS1 gene to
the photoreceptors, by subretinal (AAV5-mOP-
hRS1; mouse opsin promoter55) and intravitreal
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injections (AAV2-CMV-Rs1,56 AAV8-RS1-hRS1,57
AAV8-RS/IRBP-hRS1; under the control of RS/
interphotoreceptor binding protein promoter58 and
AAV7m8-RHO-hRS1; rhodopsin promoter59) can
lead to long-term structural and functional pres-
ervation. Nonetheless, gene transfer at advanced
stages of the disease (>7 months of age) showed no
improvements of ERG responses.60 Applied Ge-
netic Technologies Corporation recently initiated
a phase I/II clinical trial to evaluate the safety and
efficacy of intravitreal injection of AAV2tYF-CBA-
hRS1 in patients with XLRS (NCT02599922; Sup-
plementary Table S1). AAV8-RS/IRBP-hRS1 also
entered phase I/II (NCT02317887; Supplementary
Table S1).
Gene replacement therapy in models
of progressive photoreceptor disorders
Progressive photoreceptor degenerations are the
most common causes of complete blindness in hu-
mans.When inherited, they are primarily caused by
mutations in genes expressed in rods only (retinitis
pigmentosa [RP]), or in both rods and cones (LCA,
RP, and cone–rod dystrophies).61 The fact that loss
of cones is associated with the most devastating
aspect in these diseases points to the need to pre-
serve cone function and survival as the primary
therapeutic outcome. However, as cone death is in-
variably linked to the death of rods,62 the therapy
should be able in most cases to also robustly protect
rod photoreceptors from degeneration.
Mutations in the PDE6b gene, which encodes the
b subunit of the rod phosphodiesterase (PDE6) en-
zyme, are associated with one of the most common
and aggressive forms of recessive rod-initiated RP.
In the absence of PDE6b, PDE6 activity is severely
impaired and high levels of intracellular cGMP and
Ca2+ accumulate, leading to rod death. Rod dys-
functionwith early-onset degeneration is collectively
seen in all animal models of PDE6b-RP, including
the rd1,63–66 rd10,67,68 and Pde6b-H620Q69 mice, as
well as the PDE6b-deficient rod cone dysplasia
(rcd1)70,71 and cone rod dystrophy 1 (crd1) dogs.72 In
all of these models, rod loss is always followed by a
mutation-independent loss of cones.
Gene therapy approaches to delay rod death
were first employed in the rd1mouse, in which the
majority of rods are lost by 3 weeks of age. Initial
attempts to treat photoreceptor degeneration in
these mice were made using adenoviral,73,74 lenti-
viral,69,75 and AAV2 vectors.76 These gene delivery
tools result in overall poor photoreceptor transduc-
tion, and these studies revealed minimal structural
and functional ERG rescue. Using more efficient
gene delivery tools such as AAV8-RHO-hPDE6b
and AAV9-RHO-hPDE6b, long-term (13 months)
functional and structural improvements were ob-
tained after subretinal injection of rd1mice at PN9,
after removal of a confounding mutation in the
Gpr179 gene.77
Benefits of the levels and kinetics of transgene
expression were also evident in the slightly slower
degenerating rd10mouse model, where injection of
an AAV8-mPde6b (but not AAV5-mPde6b) vector at
PN14 resulted in a robust functional rescue.78 In
comparison, subretinal injection of AAV5-CMV-h-
PDE6b or AAV8-CMV-hPDE6b in the same animal
model at PN2, when rod differentiation is incom-
plete and rod transduction is inefficient (Petit L. and
Punzo C., unpublished data), had only minimal
therapeutic effects.79 Another study showed that
AAV8(Y773F), a vector that results in high levels of
transgene expression within 2–3 days in nearly
100% of rods,80 successfully altered the course of the
disease.81 In rcd1 dogs, injections of AAV5 and
AAV8 vectors expressing cPde6b under the control
of the rhodopsin kinase (RK) promoter (AAV5-
hRK1-cPde6b and AAV8-hRK1-cPde6b) resulted in
similar levels of functional and morphological res-
cue after subretinal delivery at PN20,82 for at least
40 months posttreatment.83 Intervention before the
onset of photoreceptor degeneration (PN25) and a
relatively slower progression of the disease when
compared with the mouse models may have likely
allowed for therapeutic transgene expression in a
high proportion of photoreceptors in time, inde-
pendent of the serotype used. Importance of the
quality of treatment is in agreement with results
obtained by the group of S. Tsang, who tested
whether lack of sustained benefit in the PDE6b-
deficient mouse after gene therapy is (1) because of
insufficient transduction efficiency and/or (2) be-
cause the disease is too advanced at the time of
treatment. Using a Cre-inducible Cre-loxP rescue
allele, they demonstrated that photoreceptor de-
generation in Pde6b-H620Q/LoxP is halted if DNA
recombination is initiated at early, mid, and late
stages of the disease. In this study, Pde6b expres-
sion after recombination was considered optimal/
not limiting.84
The potential of next-generation gene delivery
tools was illustrated in animal models of other
forms of severe early-onset rod–cone dystrophies
(Supplementary Table S2). The PDE6a-deficient
mouse has a faster rate of photoreceptor degen-
eration compared with the rd10 mouse, with the
loss of 30% of rods already evident by PN14. Using
AAV8(Y788F)-RHO-Pde6a, Wert et al. showed
that treatment at PN5 and PN21 resulted in
a dramatic preservation of retinal structure and
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cone function.85,86 These results were very exciting,
although the overall rescue of rod function was too
low to result in a detectable difference by ERG. The
murine model of CNGB1 retinopathy also benefited
from subretinal delivery of AAV8(Y733F)-RHO-m-
Cngb1a.87 Like rd1 mice, Cngb1-/- mice have no
recordable rod response by ERG. However, rod de-
generation progresses more slowly than in murine
models of PDE6-deficiency, as 50–70% of rods are
still present at 6 months of age. Treatment of
Cngb1-/- mice at PN14 resulted in dramatic resto-
ration of rod function, accounting for 33% of wild-
type levels corresponding to the surface of the retina
directly exposed to the vector. Improvement of the
functional component of the disease was associated
with a preservation of 50–70% of rods in treated
eyes at 12 months of age. More recently, Palfi et al.
demonstrated that AAVrh10 transduces rods com-
parably to AAV8 in a degenerating retina.88 Using
this serotype and an optimized murine rhodopsin
promoter, they showed great progress in the treat-
ment of the rhodopsin knockout mouse, compared
with similar doses of AAV5.89 Nonetheless, despite
the fact that therapeutic benefits were observed up
to 11 months after treatment with AAVrh10, de-
generation was not arrested in treated retinas.88
While most of the gene replacement therapies for
photoreceptor diseases discussed here target either
cones or rods, it is useful to treat the two photore-
ceptor subtypes simultaneously. This is because
many inherited photoreceptor degenerations are
caused bymutations in genes expressed in both rods
and cones. The short human rhodopsin kinase 1
(hRK1) promoter was the first well-defined pro-
moter able to drive efficient transgene expression in
both cell types, when used in conjunction with
AAV.90 While the efficiency of cone transduction
remains very low as compared with rod transduc-
tion, validation of this promoter in small91 and large
animal models,91–93 along with the development of
next-generation of vectors, led in the past few years
to an exponential growth of retinal gene transfer
studies targeting both rods and cones.
A case in point is the gene replacement therapy
for the retina-specific guanylate cyclase (GUCY2D),
which is expressed exclusively in rods and cones
and constitutes one of the most common causes of
LCA.61 The GC1-deficient mouse undergoes se-
vere cone dysfunction before cone degeneration.
Rods retain 30–50% of their function and do not
degenerate, because of the presence of a second
guanylate cyclase (GC2). Subretinal injection of
AAV5-CBA-bovine Gc1 at PN21 had no effect in
the GC1-deficient mouse model.94 In contrast,
AAV5-CBA-mGucy2e and AAV5-hRK1-mGucy2e
at PN14 restored 45% of cone ERG responses and
preserved cone survival for at least 9 months post-
injection.95 Subsequently, injection of AAV8-hRK1
vectors carrying the murine Gucy2e or human
GUCY2D cDNA at PN10 provided a 65% rescue of
cone ERG responses, cone vision and cone survival
for up to 6 months, as well as a 35% rescue of rod
function.96 A more recent study reported a resto-
ration of 54% and 38% of cone ERG responses in
mice treated at PN21 with AAV8-CMV-hGUCY2D
and AAV8-hRK1-hGUCY2D, respectively.91
Comparison of AAV5-hRK1-mGucy2e and
AAV8(Y733F)-hRK1-mGucy2e/hGUCY2D confirmed
the superiority of AAV8(Y733F) in restoring cone
function in Gucy2e-/- mice97 and Nrl-/- Gucy2e-/-
mice.98 This difference likely reflects the ability of
AAV8(Y733F) to drive faster transgene expression
than AAV5, and indicates that this temporal dif-
ference is important in terms of the ability to re-
store function. However, it is unclear whether
there is a higher overall number of preserved cones
and/or a better functional rescue of transduced
cones. Regarding rod function, there were no dif-
ferences between the AAV5 and the AAV8(Y733F)
vectors.
The ability of AAV8(Y733F)-hRK1-mGucy2e to
rescue both cones and rods was confirmed in the
GC1/GC2 double-deficient mouse, which exhibits
complete loss of both cone and rod ERG responses,
as well as slow degeneration of rods. Both cone and
rod ERG responses were restored to 42–44% ofwild-
type levels after treatment at PN18, and to 26–29%
of wild-type levels after treatment at PN108.
The rescue remained stable for at least 1 year
posttreatment. However, only intervention before
PN108 slowed photoreceptor degeneration.99
Interestingly, benefits of AAV8-based vectors over
AAV5 have also been observed in the RPGRiP1 (ret-
initis pigmentosa GTPase regulator interacting pro-
tein 1)-deficient100,101 and AiPL1 (aryl hydrocarbon
receptor interacting protein-like 1)-deficient102–104
mouse models of early-onset severe photoreceptor
dystrophies, but not in theRPGRIP1-deficient dog, in
which AAV5 and AAV8 gave similar therapeutic ef-
fects,93 probably reflecting differences in the kinetics
of photoreceptor loss and timing of therapeutic
transgene expression between these species.
The first evidence of the efficacy of gene re-
placement therapy in a large animal model of se-
vere photoreceptor dystrophies was obtained in the
XLPRA1 (X-linked progressive retinal atrophy)
and XLPRA2 canine models of RPGR-X-linked
RP.105,106 In these dogs, Beltran et al. evaluated
the efficacy of AAV5-hRK1-hRPGR and AAV5-
IRBP-hRPGR to mitigate retinal degeneration.105
OCULAR GENE THERAPY 569
The XLPRA1 dogs were treated at 28 weeks of age,
before any apparent signs of photoreceptor degen-
eration. In contrast, XLPRA2 dogs were treated at
the onset of the disease, which is at 5 weeks of age.
In both cases, treatment resulted in convincing
preservation of retinal structure in the vector-
exposed area for a 2-year period.105 However, the
benefits seen in XLPRA2 dogs treated with AAV5-
hRK1-hRPGR or with low dose of AAV5-IRBP-h-
RPGR were smaller likely because these animals
were treated at the onset of the disease.106 Early
evaluation of the effects of gene transfer on retinal
function was difficult, because of the long-term
preservation of functional photoreceptors in areas
not exposed by the vector.106 Nonetheless, reten-
tion of rod and cone function was clearly seen in
XLPRA2 dogs up to 3 years of age with improved
long-term vision.105
Interestingly, XLPRA2 dogs treated at 12 weeks
of age (loss of *40% of the total photoreceptors)
showed an initial decline in outer nuclear layer
(ONL) thickness, but ONL loss in the vector-
exposed area was halted from 31 weeks to 2.7 years
of age. XLPRA2 dogs treated at 26 weeks of age
(loss of 50–60% of total photoreceptors) showed a
similar profile, but with a decrease and stabiliza-
tion ofONL thickness after 52weeks of age. Ahigher
proportion of nontreated photoreceptors could
explain this delay in ONL stabilization after late
intervention. Remarkably, ERG analysis showed
preserved rod function in all 3 dogs treated at this
late stage, and preserved cone function in 2 out 3
dogs, accounting for 8% of wild-type ERG levels,
providing very exciting proof-of-concept to sup-
port a future clinical trial.105
Additional improvements
Extensive efforts have also been made to ex-
pand the applicability of gene-specific therapy in
the eye, including the treatment of photoreceptor
dystrophies caused by mutations in large genes,
the treatment of autosomal dominant retinal dis-
eases, and the delivery of transgene to a large reti-
nal surface by intravitreal injection. The reader is
referred to recent reviews for further information
about the strategies that are being devised to over-
come these limitations.107–109
BROADENING THE SPECTRUM
OF TREATABLE PATIENTS
BY THE DEVELOPMENT
OF GENE-INDEPENDENT THERAPIES
Over the last two decades, proof-of-concept stud-
ies of corrective gene therapy have been established
in many different animal models of inherited re-
tinopathies, strongly supporting further translation
fromanimalmodels to human.However, evidence of
the potency and efficacy of gene transfer to the ret-
ina at late stages of the disease is less robust. Early
physiological alteration and loss of photoreceptors
cells remain important factors limiting the thera-
peutic window for corrective gene therapy. In ad-
dition, with over 240 genes associated with retinal
degeneration in humans, targeting individually
each group of patients will likely not be possible.
Mutation-independent therapies that allow treat-
ing entire families of retinal degenerative diseases
would represent a more cost-effective approach
(Fig. 1). Current strategies that utilize gene therapy
and might be the more broadly applicable are de-
tailed below.
Preventing secondary cone death
in retinitis pigmentosa
Diseases that benefit the most from a mutation-
independent approach are those associated with
photoreceptor loss, in particular RP. The reason
why this disease context is attractive for amutation-
independent approach is that, in the vast majority
of cases, the genetic defects are specific to rod pho-
toreceptors; however, cones die as well. It is this
secondary loss of cones that causes the severe visual
disabilities and complete blindness in humans.
Consequently, gene therapies that prolong cone
function and survival for such patients would
maintain the temporal window of useful vision in a
large number of patients.
A first point of intervention that is being devel-
oped inhibits rod cell death,which should prevent or
delay the secondary loss of cones. Because the onset
of cone death always follows the major rod death
phase,62 even a small delay in the death of rods
could translate into a high preservation of cones.
One of the most straightforward ways to inhibit
cell death is to inhibit the execution of cell death
itself. Photoreceptor cell deathhas been foundunder
various stress conditions to be predominantly apo-
ptotic110 and executed by caspases.111 The X-linked
inhibitor of apoptosis (XIAP) is one of a series of
proteins that can inhibit cell death by binding to
the two executioner caspases 3 and 7 and to the
initiator caspase 9.112,113 Misexpression of XIAP by
adenoviral- or AAV2-mediated gene transfer has
been shown to delay ganglion cell death in various
rodent models of optic nerve injury114–116 and pro-
tect neurons from retinal ischemia117 and from the
mutagenN-nitroso-N-methylurea.118Most recently,
subretinal injection of AAV5-CBA-hXIAP has been
shown to prevent photoreceptor death in the P23H
rat model of dominant retinitis pigmentosa for at
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Figure 1. Gene therapy strategies for inherited retinal diseases. (A) Schematic of subretinal gene therapy delivery in human patients. (B) Possible
therapeutic interventions during the progression of inherited retinal dystrophies. (B, top) Time course of photoreceptor and/or RPE cell death. Therapeutic
strategies at each stage of the disease are indicated. At early stages of the disease, affected photoreceptors and/or RPE cells can be targeted using mutation-
specific gene therapy (gene replacement or gene suppression therapy). Photoreceptor death can also be prevented or delayed by mutation-independent
strategies, for example, the delivery of growth factors. Therapies initiated at a more advanced stage of the disease, when most of the primary affected cells are
gone, aim at targeting the common mechanism of secondary cone death. This can be done by the delivery of antioxidant genes (in cones or in other cells of the
retina if the encoded factor is secreted, e.g., RdCVF) or by the delivery of genes that boost cell metabolism. After cones have lost their outer segments and
become unresponsive to light stimulation, they can be reactivated by the introduction of NpHR. Nonphotoreceptor cells (bipolar and ganglion cells) can be
reactivated by the introduction of various optogenes. (B, bottom) Images of retinal sections of the retinal degeneration 1 (rd1) mouse model of retinitis
pigmentosa. Arrows indicate the target cells at each stage of photoreceptor death. GCL, ganglion cell layer; INL, inner nuclear layer; IS, inner segments; ONL,
outer nuclear layer; OS, outer segments; RPE, retinal pigmented epithelium.
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least 30 weeks119 and confer photoreceptor protec-
tion 2 months after sodium hylauronate-induced
retinal detachment.120
Inhibition of photoreceptor degeneration using
growth factors has also been tested. The ciliary
neurotrophic factor (CNTF) is the most studied.
CNTF has been shown to delay ganglion cell death
through direct and AAV delivery121–125 and to de-
lay photoreceptor death in various animal models
of RP.126–129 A recent study in Rho-/- mice showed
that intraocular delivery of AAV2-hCNTF can con-
fer long-term rod and cone photoreceptors protec-
tion and significantly delay vision loss even when
rod death is well advanced.130 However, themode of
action of CNTF is not fully understood, and even
though CNTF is protective in animals with photo-
receptor degeneration, high doses are associated
with an acute deconstruction of photoreceptor outer
segments131,132 and gene expression changes that
are similar to those seen in light-induced photore-
ceptor plasticity.133 Interestingly, the temporary
deconstruction of photoreceptor outer segments
appears to enhance gene transfer by AAV5 in a ca-
nine model of CNBG3-ACMH, making CNTF a po-
tential therapeutic candidate to pretreat the eye
before receiving the actual gene therapy.29 Clinical
evaluation of CNTF for the treatment of retinal
degeneration has been already conducted using
encapsulated cell implants in patients with ad-
vanced stages of RP (NCT00063765). In this phase 1
study, 10 patients received the implants in one eye
for 6 months without major side effects.134 Subse-
quently, three phase 2 clinical trials for early RP
(NCT00447980, 68 patients), lateRP (NCT00447993,
65 patients), and geographic atrophy (NCT00447954,
39 patients) were initiated. Data at 2 years post-
implantation demonstrated that expression of CNTF
was maintained over 24 months, with no serious
adverse effects.135,136 In patients with early-stage
RP, no protection of rods has been demonstrated.
Macular cone photoreceptors remained stable over
12–35months, when sham-treated eyes experience
a 9–24% decrease in cone number; however, this
protective effect was not associatedwith detectable
changes in visual acuity and ERG responses.137
Determining final outcomes of the therapy on
cone survival will require a longer follow-up be-
cause of the slow progressive nature of RP. If
successful, AAV-mediated CNTF gene therapies
may follow.
Besides the classical neuroprotective factors,
both AAV-mediated delivery of erythropoietin
(EPO), a cytokine that is upregulated during hyp-
oxia, and AAV-mediated delivery of proinsulin
have been shown to have neuroprotective proper-
ties in several models of RP.138–140 Interestingly,
however, only AAV-mediated systemic adminis-
tration of EPO but not intraocular administration
appears to be protective.141 To translate this into a
human gene therapy, EPO derivatives have been
used that were protective after subretinal delivery
by AAV in various models of retinal degenera-
tion.139 However, how applicable EPO derivatives
and proinsulin are for a human therapy remains to
be determined.
A second point of intervention targets cones di-
rectly to protect them from degeneration once the
majority of rods have died. This requires an un-
derstanding of the mechanism of cone death, for
which several models have been proposed. Some of
these models seem to converge around energy
availability and the associated redox potential (for
review see ref.142).
Originally, it was believed that rods produce a
trophic factor that is required for cone survival
simply because cone death always follows rod death,
regardless of the circumstances that lead to rod
death. Identification of such factor would inevi-
tably provide a unifying therapy for all forms of RP
that are caused bymutations in rod-specific genes.
In 2004, the rod-derived cone viability factor
(RdCVF),143 encoded by the nucleoredoxin-like 1
(NXNL1) gene, was identified and since hasmoved
from the proof-of-concept as an injectable trophic
factor that can delay cone death143,144 into an AAV-
mediated gene therapeutic approach.145 RdCVF is a
thioredoxin-like protein with two isoforms146 and
was initially believed to reduce oxidative stress, a
disease condition that accompanies the degenera-
tion of rods and cones because of the massive loss of
rods.142 Meanwhile, the protein has been shown to
indirectly interact with the glucose transporter-1,
thereby promoting glucose uptake in cones during
the period of cone degeneration.147 This finding is in
line with one of the proposed mechanisms of sec-
ondary cone death, which postulates that cones are
nutrient deprived; in particular, they are short of
glucose.62,148 Systemic intravenous delivery to rd10
mice of AAV92YF-CAG-Nxnl1 at PN1 resulted
in improved cone-mediated ERG responses and
cone survival at 1month of age. In the samemouse
model, intravitreal injection at PN14 of a novel
AAV2 variant with increased photoreceptor cells
tropism, 7m8-CAG-Nxnl1, also resulted in good
preservation of cone function and survival 1 month
posttreatment.145 Clinical trials will undoubtedly
determine if RdCVF becomes a therapeutic agent
with broad applicability in humans.
The realization that oxidative stress is a con-
tributing factor to secondary cone death149 led to
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extensive research in antioxidant therapies,many of
which have shownpromising results inmouse.150,151
In humans, various combinations of vitamins and
omega-3 fatty acids have been tested, showing
a slight effect in delaying the disease progres-
sion.152–154 However, the problem with orally sup-
plemented antioxidants is that they may never
reach critical concentrations in the tissue of inter-
est. This circumstance, as well as the finding that
antioxidant enzymes may need to be present in the
right combination155 directly in sick cones to reduce
oxidative stress,156 led to the first AAV-mediated
approaches in which various enzymes and tran-
scription factors that regulate the expression of
detoxifying enzymes were tested.155,157 The most
promising of these candidates, nuclear factor
erythroid-derived 2 like 2 (NRF2), showed a re-
markable delay in cone death in twomousemodels
of RP, opening the door for a new mutation-
independent approach for secondary cone death.
By investigating the molecular mechanisms of
secondary cone death, we recently revealed that
cones are nutrient deprived inRP,62 a finding that is
in line with the increase in oxidative stress seen in
cones during degeneration,149 since lack of glucose
reduces the redox potential of a cell.142 Because rods
account for over 95% of all photoreceptors, we pro-
posed that once a critical threshold of rod death is
breached, cone death initiates a cell autonomous
event caused by the collapse of the relatively few
cone–RPE interactions reducing nutrient flow to
cones.142 This model explains why cones may sur-
vive for extended periods in the cone-rich central
retina of patients and large animal models of RP,
despite the total loss of rods, and why cone-specific
diseases do not lead to rod degeneration. Genetic
hyperactivation of a key kinase that promotes cell
metabolism, the kinase mechanistic target of rapa-
mycin complex 1 (mTORC1), has led to a remark-
able delay of cone death for at least 8 months of age
in two mouse models of RP.148 The data represent
the most profound and long-lasting effect of cone
survival seen thus far, strongly suggesting that
boosting cellmetabolism in cones is a viable strategy
to prolong cone survival in RP.158 A targeted gene
therapy approach that augments mTORC1 target
genes in cones is currently under development. In-
terestingly, extending cell autonomous cone sur-
vival may go beyond RP and hold promise for many
other degenerative diseases, such as age-related
macular degeneration (AMD).159 In these diseases,
once a critical number of photoreceptors have died
in a specific region, the remaining healthy photo-
receptors in that region may be affected by reduced
nutrient flow, as are cones in RP. In addition, the
degeneration of rescued photoreceptors observed in
RPE65-treated patients may involve a similar
mechanism of cone death to the one in RP.28
Restoration of visual sensitivity
by optogenetics
Restoration of vision through optogenetics pro-
vides an interesting strategy to restore visual per-
ception in blind retinas (see reviews160,161). This
therapeutic approach relies on delivering a gene
encoding a light-sensitive channel protein (micro-
bial opsins, endogenous opsins, or synthetic light-
sensitive ion channels) to either reactivate dormant
cones or activate other retinal neurons at late stages
of degeneration.
Opsin-likemicrobial proteins have the advantage
to reversibly isomerize a vitamin A derivate as the
chromophore.162 In response to light, microbial op-
sins can thus independently induce changes in the
membrane potential of a cell allowing the electrical
signal to propagate to the brain. Channelrhodospin
(CHR2) was the first microbial opsin to be used
in the retina. CHR2 pumps cations upon excitation
by light and produces excitatory currents. AAV-
mediated expression of CHR2 at the level of ON
bipolar cells163–167 and ganglion cells168 in mouse
models of RP successfully restored light-evoked po-
tentials in treated retinas. While transduction of
ganglion and bipolar cells is still difficult in large
animal models, novel vectors and promoters with
better affinity for the inner retina have been re-
cently reported.166,169,170 Moreover, good preserva-
tion of these cells has been demonstrated in patients
with advanced RP and LCA.171 Another approach is
to reactivate nonfunctional ‘‘dormant’’ cone photo-
receptors using halorhodospins, which produce in-
hibitory currents.172 This strategy may restore
visual processing in all layers of the retina. How-
ever, it remains to be determined who is an appro-
priate patient for this procedure as many RP
patients keep functional cones for decades and the
remodeling of the retinal network upon loss of
photoreceptors could make this approach challeng-
ing in humans.173 In addition, long-term effects of
membrane potential depolarization/repolarization
on nutrient-deprived cones remain unexplored.
Despite these advances, one problem microbial
optogenetics faces is the light sensitivity and dy-
namic range of these various channels. Recently, a
new generation of synthetic light-acting channels
has been described that use azobenzene-based light
switches fused to ion channels or receptors.174–176
One such approach remodeled the ionotropic gluta-
mate receptor177 restoring visual functionat the level
of ganglion cells178 and bipolar cells.179 Initially,
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optogenetics was introduced in 2002 by simulta-
neous coexpression of the Drosophila rhodopsin,
arrestin-2, and the alpha subunit of the G-protein
to activate culture hippocampal neurons by light.180
The approach never gained much favorability over
the microbial opsins because it requires a triple
transduction, something that remains difficult to
achieve in the retina. However, the idea of using
endogenous G-protein-coupled receptors (GPCR)
such as melanopsin,181 which is involved in circa-
dian rhythm and the pupillary reflex182 and is nat-
urally expressed in a subset of ganglion cells, has
been revisited on the premise that other cells may
express some of the components needed to activate
the cascade with a GPCR. Recent experiments have
shown that, when rhodopsin is delivered to bipolar
cells, light sensitivity is restored by 2–3 orders of
magnitude lower than what can be achieved by the
microbial channels, making this a feasible approach
to restore vision in late stages of RP.183
Antiangiogenic gene therapy
for acquired retinopathies
The most successful mutation-independent ap-
proach thus far has been applied to two diseases,
neither of which is caused by a specific mutation
but rather by a combination of genetic and envi-
ronmental risk factors. Wet AMD184 and diabetic
retinopathy (DR)185 are both characterized by for-
mation of new blood vessels of the choroidal and
retinal vasculature, respectively. The subsequent
leakage of fluid from these newly formed blood
vessels into the retinal proper is what generally
causes massive neuronal loss. The realization that
vascular endothelial growth factor (VEGF) is one of
the key culprits in promoting the disease pathology
has led to the development of anti-VEGF therapies
with first-generation therapies utilizing anti-VEGF
antibodies (Lucentis [approved in 2006 for wet
AMD] and Avastin [Genetech], Avastin being the
parent molecule of Lucentis) that are administered
intravitreally. However, the therapy requires con-
tinuous administration on an interval of 4–8 weeks,
is costly, is associated with potential side effects
from the repeated injections, and is a burden for
patients because of the many clinical visits. Hence,
gene therapeutic approaches have been established
to either target VEGF itself, by viral-mediated
overexpression of the soluble ligand binding part
of the vascular endothelial growth factor receptor 1
gene (FLT1),186–192 or by inhibiting its action
through use of angiogenesis inhibitors such as pig-
ment epithelium-derived factor (PEDF)193–195 or a
combination of two angiostatic factors, angiosta-
tin and endostatin.196 All three gene therapy ap-
proaches have since moved to the clinic. Because
of its vast experimental evidence in animal mod-
els186–192 and preclinical trials,197 expression of
sFLT1 by AAV2-mediated gene transfer is the most
advanced approach with two ongoing clinical trials.
Avalanche-Lions Institute is evaluating an alter-
natively spliced form of FLT1, using the subretinal
route (NCT01494805). Published results at 1 year
posttreatment indicate that 4 out of 6 patients did
not require any rescue injections with anti-VEGF
antibodies.198 Genzyme uses intravitreal delivery
(NCT01024998). In parallel, Oxford Biomedica is
evaluating the efficacy of simultaneous expression
of angiostatin and endostatin by subretinal injection
of EIAV-LV (RetinoStat, NCT01301443).
CONCLUSION AND FUTURE PROSPECTS
Despite existing limitations and questions that
still need to be addressed and resolved, gene ther-
apy for ocular diseases continues to show great
promise for the future. Current clinical studies of
gene replacement therapy, although not all are
convincing in terms of longevity of therapeutic ef-
fects, have demonstrated a good safety record. They
provide evidence that it is possible to obtain clini-
cally relevant visual improvements after gene re-
placement. With the recent improvements in AAV
vectors and the increase in therapeutic benefits
observed in preclinical studies, new clinical trials
should translate into evenmore encouraging results
in patients. During the next decade, a better un-
derstanding of themechanisms that commonly limit
the efficacy of gene replacement therapy over the
long-term will be a key aspect that needs to be
solved to move forward with retinal gene replace-
ment therapies. Simultaneously, lessons learned
from the biology of retinopathies should enable the
development of viable therapeutic strategies to
prolong vision independently of the disease-causing
mutations, further encouraging transfer to clinical
trials.With the advent of genome editing technology
for gene and cell therapy, future studies should also
be aimed at safe and long-term AAV-mediated de-
livery of genome-modifying components to the tar-
get cell types in the eye, as well as other organs.
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